Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Regulus Therapeutics

05/05/2025 21:04

Regulus Therapeutics Inc RGLS.OQ RGLS.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Regulus Therapeutics Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Regulus Therapeutics Inc is $9.00​, above​ its last closing price of $7.85. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.21
-0.20
Beat
4.8
Sep. 30 2024
-0.18
-0.17
-0.21
Missed
-23.5
Jun. 30 2024
-0.16
-0.15
-0.17
Missed
-15.9​
Mar. 31 2024
-0.26
-0.22
-0.29
Missed
-30.3
​​Dec. 31 2023
-0.40
-0.39
-0.40
Missed
-1.3
Sep. 30 2023
-0.41
-0.40
-0.40
Met
-0.8​
Jun. 30 2023
-0.41
-0.41
-0.37
Beat
9.8
Mar. 31 2023
-0.44
-0.44
-0.42
Beat
3.8

This summary was machine generated May 5 at 20:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)